Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Erschienen in
-
In: Clinical Chemistry and Laboratory Medicine, Band 47, Ausgabe 9, Seite 1117-1123, 2009
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin
- (wer)
-
Humboldt-Universität zu Berlin
- (wann)
-
2009
- Urheber
-
Sørensen, Patricia Diana
Jakobsen, Erik Hugger
Langkjer, Sven Tyge
Bokmand, Susanne
Østergaard, Birthe
Olsen, Dorte Aalund
Madsen, Jonna Skov
Brandslund, Ivan
- DOI
-
10.1515/CCLM.2009.241
- URN
-
urn:nbn:de:kobv:11-100132184
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sørensen, Patricia Diana
- Jakobsen, Erik Hugger
- Langkjer, Sven Tyge
- Bokmand, Susanne
- Østergaard, Birthe
- Olsen, Dorte Aalund
- Madsen, Jonna Skov
- Brandslund, Ivan
- Humboldt-Universität zu Berlin
Entstanden
- 2009
Ähnliche Objekte (12)
Clinical oncology in resource-limited settings
Reporting oncoimaging in the appropriate oncology setting
Safety of Polysorbate 80 in the Oncology Setting
Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data
Ambulatory routine care in oncology in Germany: real-world survival data
Ambulatory routine care in oncology in Germany: real-world survival data
AVAiLABLE NIS – AVASTIN® in lung cancer treatment in routine oncology practice in Germany
Evaluation and interpretation of very low voriconazole concentrations in routine therapeutic drug monitoring
Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting
MS-MLPA analysis for FMR1 gene: evaluation in a routine diagnostic setting
Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic
A scoping review examining the integration of exercise services in clinical oncology settings
Clinical oncology in resource-limited settings
Reporting oncoimaging in the appropriate oncology setting
Safety of Polysorbate 80 in the Oncology Setting
Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data
Ambulatory routine care in oncology in Germany: real-world survival data
Ambulatory routine care in oncology in Germany: real-world survival data
AVAiLABLE NIS – AVASTIN® in lung cancer treatment in routine oncology practice in Germany
Evaluation and interpretation of very low voriconazole concentrations in routine therapeutic drug monitoring
Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting
MS-MLPA analysis for FMR1 gene: evaluation in a routine diagnostic setting
Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic
A scoping review examining the integration of exercise services in clinical oncology settings
Clinical oncology in resource-limited settings
Reporting oncoimaging in the appropriate oncology setting
Safety of Polysorbate 80 in the Oncology Setting
Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data
Ambulatory routine care in oncology in Germany: real-world survival data
Ambulatory routine care in oncology in Germany: real-world survival data
AVAiLABLE NIS – AVASTIN® in lung cancer treatment in routine oncology practice in Germany
Evaluation and interpretation of very low voriconazole concentrations in routine therapeutic drug monitoring
Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting
MS-MLPA analysis for FMR1 gene: evaluation in a routine diagnostic setting
Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic